Objective:

The article examines the objective, findings, and clinical context described in AAO: VisiPlate Shows Staying Power.

Approach:

• Study design: VITA is a prospective, single-arm, multicenter, open-label clinical trial conducted at three sites in South Africa.
• Device: VisiPlate is an ultrathin, multichannel shunt designed to drain aqueous humor from the anterior chamber.
• Presentation: Jonathan S. Myers presented the two-year follow-up at the 2026 American Academy of Ophthalmology Annual Meeting.

Key Findings:

• The AAO presentation extended VITA follow-up to two years; the context does not provide specific efficacy or safety results.
• The device’s microchannels are intended to maintain aqueous flow while reducing obstruction risk.

Interpretation:

The two-year follow-up adds longer-term clinical observation as Avisi continues evaluating VisiPlate in its clinical development program.

Limitations:

• The study is single-arm and open-label.
• The provided context does not report numerical outcomes or detailed safety findings.

Sources:

• Article context